谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.

Le Wang,George A. Doherty,Andrew S. Judd,Zhi-Fu Tao,T. Matthew Hansen,Robin R. Frey,Xiaohong Song,Milan Bruncko,Aaron R. Kunzer,Xilu Wang,Michael D. Wendt,John A. Flygare,Nathaniel D. Catron,Russell A. Judge,Chang H. Park,Shashank Shekhar,Darren C. Phillips,Paul Nimmer,Morey L. Smith,Stephen K. Tahir,Yu Xiao,John Xue,Haichao Zhang, Phuong N. Le,Michael J. Mitten,Erwin R. Boghaert,Wenqing Gao,Peter Kovar,Edna F. Choo,Dolores Diaz,Wayne J. Fairbrother,Steven W. Elmore,Deepak Sampath,Joel D. Leverson,Andrew James Souers

ACS Medicinal Chemistry Letters（2020）

引用 76|浏览61
关键词
BCL-X-L,BCL-2,apoptosis,A-1331852,A-1155463,structure-based drug design (SBDD)
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要